Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma

Bibliographic Details
Main Authors: Diego Bagnasco, Massimiliano Povero, Lorenzo Pradelli, Enrico Heffler, Marco Caminati, Francesco Menzella, Giovanni Rolla, Manlio Milanese, Carlo Lombardi, Elisa Testino, Gianenrico Senna, Giorgio Walter Canonica, Giovanni Passalacqua
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:World Allergy Organization Journal
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455120302799
id doaj-747d44f2d43c4dcd98ac4240a81bc39b
record_format Article
spelling doaj-747d44f2d43c4dcd98ac4240a81bc39b2020-11-25T03:22:18ZengElsevierWorld Allergy Organization Journal1939-45512020-08-01138100376Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthmaDiego Bagnasco0Massimiliano Povero1Lorenzo Pradelli2Enrico Heffler3Marco Caminati4Francesco Menzella5Giovanni Rolla6Manlio Milanese7Carlo Lombardi8Elisa Testino9Gianenrico Senna10Giorgio Walter Canonica11Giovanni Passalacqua12Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa ItalyAdRes, Turin ItalyAdRes, Turin ItalyDepartment of Internal Medicine, Respiratory Disease Clinic, IRCCS Humanitas Clinical and Research Center, Humanitas University, Milan ItalyAsthma Center and Allergy Unit, Verona University and General Hospital, Verona ItalyUnità Operativa di Pneumologia, Arcispedale Santa Maria Nuova, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia ItalyAllergy and Immunology, AO Mauriziano Hospital, University of Turin, Turin ItalyDivision of Pneumology, S.Corona Hospital, Pietra Ligure, Pietra Ligure ItalyDepartmental Unit of Allergology & Respiratory Diseases, Fondazione Poliambulanza, Brescia ItalyDepartment of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa ItalyAsthma Center and Allergy Unit, Verona University and General Hospital, Verona ItalyDepartment of Internal Medicine, Respiratory Disease Clinic, IRCCS Humanitas Clinical and Research Center, Humanitas University, Milan ItalyDepartment of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa Italyhttp://www.sciencedirect.com/science/article/pii/S1939455120302799
collection DOAJ
language English
format Article
sources DOAJ
author Diego Bagnasco
Massimiliano Povero
Lorenzo Pradelli
Enrico Heffler
Marco Caminati
Francesco Menzella
Giovanni Rolla
Manlio Milanese
Carlo Lombardi
Elisa Testino
Gianenrico Senna
Giorgio Walter Canonica
Giovanni Passalacqua
spellingShingle Diego Bagnasco
Massimiliano Povero
Lorenzo Pradelli
Enrico Heffler
Marco Caminati
Francesco Menzella
Giovanni Rolla
Manlio Milanese
Carlo Lombardi
Elisa Testino
Gianenrico Senna
Giorgio Walter Canonica
Giovanni Passalacqua
Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
World Allergy Organization Journal
author_facet Diego Bagnasco
Massimiliano Povero
Lorenzo Pradelli
Enrico Heffler
Marco Caminati
Francesco Menzella
Giovanni Rolla
Manlio Milanese
Carlo Lombardi
Elisa Testino
Gianenrico Senna
Giorgio Walter Canonica
Giovanni Passalacqua
author_sort Diego Bagnasco
title Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
title_short Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
title_full Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
title_fullStr Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
title_full_unstemmed Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
title_sort clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
publisher Elsevier
series World Allergy Organization Journal
issn 1939-4551
publishDate 2020-08-01
url http://www.sciencedirect.com/science/article/pii/S1939455120302799
work_keys_str_mv AT diegobagnasco clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT massimilianopovero clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT lorenzopradelli clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT enricoheffler clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT marcocaminati clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT francescomenzella clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT giovannirolla clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT manliomilanese clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT carlolombardi clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT elisatestino clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT gianenricosenna clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT giorgiowaltercanonica clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
AT giovannipassalacqua clinicaleconomicimpactofmepolizumabinpatientswithseverehypereosinophilicasthma
_version_ 1724610051537108992

Similar Items